---
figid: PMC9311918__antioxidants-11-01304-g004
pmcid: PMC9311918
image_filename: antioxidants-11-01304-g004.jpg
figure_link: /pmc/articles/PMC9311918/figure/antioxidants-11-01304-f004/
number: Figure 4
figure_title: ''
caption: 'Timeline of mTOR inhibitors from discovery to the clinic for the treatment
  of ocular neurodegenerative diseases. Abbreviations: AMD, age-related macular degeneration;
  CNV, choroidal neovascularization; EGCG, epigallocatechin gallate; HG, high glucose;
  GA, geographic atrophy; MMXM, Mingmu Xiaomeng; OCT, octreotide; OPTN, optineurin;
  RGC, retinal ganglion cell; rMCs, retinal MÃ¼ller cells. References in the figure:
  1992 [], 1990 [], 1991 [], 1997 [], 2002 [], 2009 [], 2010 * [], 2010 ** [], 2013
  * [], 2013 ** [], 2014 * [], 2014 ** [], 2015 * [], 2015 ** [], 2016 * [], 2016
  ** [], 2018 [], 2019 * [], 2019 ** [], 2021 * [], 2021 ** [], 2021 *** [].'
article_title: 'mTOR Signalling Pathway: A Potential Therapeutic Target for Ocular
  Neurodegenerative Diseases.'
citation: Yipin Wang, et al. Antioxidants (Basel). 2022 Jul;11(7):1304.
year: '2022'

doi: 10.3390/antiox11071304
journal_title: Antioxidants
journal_nlm_ta: Antioxidants (Basel)
publisher_name: MDPI

keywords:
- mTOR
- AMD
- DR
- glaucoma
- oxidative stress
- hypoxia
- inflammation
- ROS
- rapamycin
- clinical trial

---
